Biostem Technologies Inc (BSEM)

$6.74 +0.50 (8.01%)
Market Cap 104.94M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 7.91
Forward PE 23.17
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 90,000
Avg Vol 119,018
Day's Range N/A - N/A
Shares Out 16.82M
Stochastic %K 50%
Beta -0.38
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
4901 Northwest 17th Way, Suite 606, Fort Lauderdale, United States
FonsieTrader
FonsieTrader Jul. 1 at 4:49 PM
Why $BSEM Must Stay On Your Radar in 2026 ? Even on this temporary weakness, the fundamentals are screaming opportunity: - 7 Consecutive Profitable Quarters - Elite 88.5% Gross Margins - $10.5M Quarterly Revenue Run-Rate - $40M Transformational BioTissue Acquisition adding Neox® & Clarix® + ~$29M incremental revenue - Aggressive expansion into hospitals, ASCs, burns & trauma - Nasdaq Uplisting Focus + Zacks $25.50 Price Target Rare profitable small-cap in regenerative medicine with strong execution and major catalysts ahead. Dips like this are exactly why smart money keeps $BSEM on radar. Who else is holding or adding $BSEM? Drop your thoughts Communicated Disclaimer / Sponsored Content https://shorturl.at/CJgAX
0 · Reply
FonsieTrader
FonsieTrader Jul. 1 at 3:00 PM
🚀 $BSEM ON STRONG SUPPORT — OVERSOLD SKYROCKET SETUP! Weekly chart showing price perfectly holding the bottom range under extremely oversold conditions. Classic triple bottom = low risk, high reward! Why $BSEM Could Explodes Higher Anytime: ✅ 7 Consecutive Profitable Quarters + 88.5% Gross Margins ✅ $40M BioTissue Acquisition adding Neox® & Clarix® + $29M incremental revenue ✅ Expanding into hospitals, ASCs, burns & trauma ✅ Nasdaq Uplisting Focus 2026 + Zacks $25.50 Target Was trading $8+ in January — easy path back soon! OTC player with strong fundamentals and catalysts primed for extreme volatility. Communicated Disclaimer / Sponsored Content https://shorturl.at/CJgAX
0 · Reply
FonsieTrader
FonsieTrader Jul. 1 at 1:30 PM
$BSEM TRIPLE BOTTOM + TRANSFORMATIONAL 2026 CATALYSTS! BioStem Technologies is executing at elite level: ✅ $40M Transformational BioTissue Acquisition adding Neox® & Clarix® ✅ Expanding into hospitals, ASCs, burns, trauma & soft-tissue repair ✅ 7 Consecutive Profitable Quarters + 88.5% Gross Margins ✅ $10.5M Quarterly Revenue Run-Rate + $29M Incremental from Acquisition ✅ Nasdaq Uplisting Focus + Zacks $25.50 Price Target Technical: Classic triple bottom on weekly chart = strong support & breakout setup. Low risk entry with huge upside to $25+ as catalysts hit in 2026. Rare profitable small-cap in regenerative medicine with proprietary perinatal allografts. Smart money accumulating now! Let's ride toward $6.00! Communicated Disclaimer: https://shorturl.at/CJgAX
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Jul. 1 at 1:19 PM
OTC: $BSEM On Watch (TRIPLE BOTTOM) *Sponsored Watching BioStem Technologies heading into 2026. • 7 straight profitable quarters • Potential NASDAQ uplisting • Zacks $25.50 price target • Up to $40M acquisition expands wound care platform • Expected ~$29M annual revenue contribution Communicated Disclaimer: https://www.ztradez.net/communicated-disclaimer2
0 · Reply
Biotech80
Biotech80 Jun. 30 at 8:54 PM
$BSEM
0 · Reply
MRSUNNY
MRSUNNY Jun. 25 at 9:35 PM
$BSEM anything under $4 is a steal
0 · Reply
GlobalInsights
GlobalInsights Jun. 8 at 9:23 PM
$BSEM Looks like 52w low is in sight
0 · Reply
IRISHMIKE1
IRISHMIKE1 May. 20 at 12:01 AM
$BSEM So with no update really on uplifting and the Acquisition of Bio Tissue Holding completed, I’m guessing we need to wait till August for both Improved Earnings as well as Uplifting of stock to Nasdaq!!!
0 · Reply
MarketBeat
MarketBeat May. 16 at 3:07 AM
https://marketbeat.com/a/8657239/ $BSEM BioStem Technologies Q1 Earnings Call Highlights
0 · Reply
GlobalInsights
GlobalInsights May. 15 at 1:58 PM
$BSEM The snake oil selling executive team keeps trying to convince people the future is great. Well it’s unlikely. I don’t see how they can get on the Nasdaq after misrepresenting their financial statements over the last couple of yrs. Have the executives compensation been clawed back for that misrepresentation?
0 · Reply
Latest News on BSEM
No data available.
FonsieTrader
FonsieTrader Jul. 1 at 4:49 PM
Why $BSEM Must Stay On Your Radar in 2026 ? Even on this temporary weakness, the fundamentals are screaming opportunity: - 7 Consecutive Profitable Quarters - Elite 88.5% Gross Margins - $10.5M Quarterly Revenue Run-Rate - $40M Transformational BioTissue Acquisition adding Neox® & Clarix® + ~$29M incremental revenue - Aggressive expansion into hospitals, ASCs, burns & trauma - Nasdaq Uplisting Focus + Zacks $25.50 Price Target Rare profitable small-cap in regenerative medicine with strong execution and major catalysts ahead. Dips like this are exactly why smart money keeps $BSEM on radar. Who else is holding or adding $BSEM? Drop your thoughts Communicated Disclaimer / Sponsored Content https://shorturl.at/CJgAX
0 · Reply
FonsieTrader
FonsieTrader Jul. 1 at 3:00 PM
🚀 $BSEM ON STRONG SUPPORT — OVERSOLD SKYROCKET SETUP! Weekly chart showing price perfectly holding the bottom range under extremely oversold conditions. Classic triple bottom = low risk, high reward! Why $BSEM Could Explodes Higher Anytime: ✅ 7 Consecutive Profitable Quarters + 88.5% Gross Margins ✅ $40M BioTissue Acquisition adding Neox® & Clarix® + $29M incremental revenue ✅ Expanding into hospitals, ASCs, burns & trauma ✅ Nasdaq Uplisting Focus 2026 + Zacks $25.50 Target Was trading $8+ in January — easy path back soon! OTC player with strong fundamentals and catalysts primed for extreme volatility. Communicated Disclaimer / Sponsored Content https://shorturl.at/CJgAX
0 · Reply
FonsieTrader
FonsieTrader Jul. 1 at 1:30 PM
$BSEM TRIPLE BOTTOM + TRANSFORMATIONAL 2026 CATALYSTS! BioStem Technologies is executing at elite level: ✅ $40M Transformational BioTissue Acquisition adding Neox® & Clarix® ✅ Expanding into hospitals, ASCs, burns, trauma & soft-tissue repair ✅ 7 Consecutive Profitable Quarters + 88.5% Gross Margins ✅ $10.5M Quarterly Revenue Run-Rate + $29M Incremental from Acquisition ✅ Nasdaq Uplisting Focus + Zacks $25.50 Price Target Technical: Classic triple bottom on weekly chart = strong support & breakout setup. Low risk entry with huge upside to $25+ as catalysts hit in 2026. Rare profitable small-cap in regenerative medicine with proprietary perinatal allografts. Smart money accumulating now! Let's ride toward $6.00! Communicated Disclaimer: https://shorturl.at/CJgAX
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Jul. 1 at 1:19 PM
OTC: $BSEM On Watch (TRIPLE BOTTOM) *Sponsored Watching BioStem Technologies heading into 2026. • 7 straight profitable quarters • Potential NASDAQ uplisting • Zacks $25.50 price target • Up to $40M acquisition expands wound care platform • Expected ~$29M annual revenue contribution Communicated Disclaimer: https://www.ztradez.net/communicated-disclaimer2
0 · Reply
Biotech80
Biotech80 Jun. 30 at 8:54 PM
$BSEM
0 · Reply
MRSUNNY
MRSUNNY Jun. 25 at 9:35 PM
$BSEM anything under $4 is a steal
0 · Reply
GlobalInsights
GlobalInsights Jun. 8 at 9:23 PM
$BSEM Looks like 52w low is in sight
0 · Reply
IRISHMIKE1
IRISHMIKE1 May. 20 at 12:01 AM
$BSEM So with no update really on uplifting and the Acquisition of Bio Tissue Holding completed, I’m guessing we need to wait till August for both Improved Earnings as well as Uplifting of stock to Nasdaq!!!
0 · Reply
MarketBeat
MarketBeat May. 16 at 3:07 AM
https://marketbeat.com/a/8657239/ $BSEM BioStem Technologies Q1 Earnings Call Highlights
0 · Reply
GlobalInsights
GlobalInsights May. 15 at 1:58 PM
$BSEM The snake oil selling executive team keeps trying to convince people the future is great. Well it’s unlikely. I don’t see how they can get on the Nasdaq after misrepresenting their financial statements over the last couple of yrs. Have the executives compensation been clawed back for that misrepresentation?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 14 at 10:17 PM
$BSEM Q1 '26 Earnings Results & Recap BioStem Technologies expects full year 2026 revenue to range from $25M to $29M, with sequential growth in both hospital and physician office businesses anticipated in the second half of 2026.
0 · Reply
EarningsInsider
EarningsInsider May. 14 at 9:31 PM
https://www.marketbeat.com/earnings/reports/2026-5-14-biostem-technologies-inc-stock/ $BSEM BioStem Technologies Earnings Transcript
0 · Reply
luckydog2
luckydog2 Apr. 25 at 5:50 PM
$CELU $NXGL $BSEM Strategic Shift Positions Celularity For Success https://www.reddit.com/r/CelularityNews/s/yyn3zOgi1b
0 · Reply
JTE_Theta
JTE_Theta Apr. 22 at 1:45 PM
$BSEM — Underrated MedTech setup 👇 🧬 WHAT THEY DO: Placental derived tissue products for chronic & acute wound care. Their BioREtain process preserves key growth factors, with RCT data showing materially better outcomes vs standard care. They’ve also expanded into surgical applications after acquiring BioTissue’s portfolio (Neox+ Clarix), giving them exposure across clinics, hospitals, and OR settings. 📊 THE NUMBERS: • 7 consecutive profitable quarters • 97% gross margins (Q4 2025) • $16M cash post deal • Acquired assets generating $29M annually • BioTissue segment already EBITDA positive 🎯 $25.50 PT Zacks sees ~355%+ upside on profitability, clinical traction & growth. CATALYST: NASDAQ UPLIST Audited financials filed (KPMG), Form 10 submitted, and application underway. CommunicationDisclaimer:http://tinyurl.com/muaeeetn
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Apr. 22 at 1:19 PM
(OTC: $BSEM) BioStem Technologies Watching this in 2026 for the $25 target and uplisting potential ✅7 straight profitable quarters ✅$25.50 Zacks target ✅Nasdaq uplisting in focus BSEM kicked off 2026 with a major acquisition valued at up to $40M, adding Neox® and Clarix® while expanding into hospital based wound care. With 88.5% gross margins, $10.5M quarterly revenue, and expected added annual revenue from the deal, this is a profitable small cap worth watching. Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $BYND $OPEN
0 · Reply
GmanPA
GmanPA Apr. 7 at 11:03 PM
$BSEM Per Barchart: Support & Resistance 3rd Resistance Point 7.4765 2nd Resistance Point 6.7833 1st Resistance Point 6.2366 Last Price 5.6900 1st Support Level 4.9967 2nd Support Level 4.3035 3rd Support Level 3.7568
0 · Reply
IRISHMIKE1
IRISHMIKE1 Apr. 7 at 8:41 PM
$BSEM Alright ! Back up over $5 ! We should continue on up over $6. With the forward guidance given with earnings we know we are headed up. The uplifting should be announced fairly soon!
0 · Reply
prismmarketview
prismmarketview Apr. 2 at 4:32 PM
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders. Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers. Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies. Other Notable Movers: BioStem Technologies ( $BSEM) up 16% Korro Bio ( $KRRO) up 10% Lipocine Inc ( $LPCN) down -78% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
0 · Reply
idkmikes57
idkmikes57 Apr. 1 at 3:51 PM
$BSEM
0 · Reply